Compare
Enveric Biosciences, Inc. vs Petros Pharmaceuticals, Inc. vs Azitra, Inc. vs Quantum Cyber N.V.
| Latest fiscal year | Enveric Biosciences, Inc. ENVB | Petros Pharmaceuticals, Inc. PTPI | Azitra, Inc. AZTR | Quantum Cyber N.V. QUCY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $0 | $537.1K |
| Revenue growth (YoY) | n/a | n/a | -100.0% | -39.9% |
| Gross margin | n/a | n/a | n/a | 72.6% |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$8.77M | $1.91M | -$10.96M | -$16.21M |
| EPS (Diluted) | -$36.24 | -$1.56 | -$2.25 | -$2.70 |
| Operating cash flow | -$8.14M | -$6.73M | -$11.22M | -$10.98M |
| Free cash flow | n/a | n/a | -$11.25M | -$10.98M |
| Cash & equivalents | n/a | $5.14M | $2.07M | n/a |
| Total assets | $5.10M | $5.16M | $5.03M | $5.33M |
| Total liabilities | n/a | $2.29M | $1.22M | $4.69M |
| Shareholders' equity | $4.18M | $2.87M | $3.80M | $641.6K |
| Return on year-end equity | -210.0% | 66.7% | -288.2% | n/m |
| Shares outstanding | 1.06M | 42.28M | 10.74M | 9.78M |
Revenue, most recent five fiscal years
| Fiscal year | Enveric Biosciences, Inc. | Petros Pharmaceuticals, Inc. | Azitra, Inc. | Quantum Cyber N.V. |
|---|---|---|---|---|
| Latest | $39.91M Ended 2019-12-31 | $5.11M Ended 2024-12-31 | $0 Ended 2025-12-31 | $537.1K Ended 2025-12-31 |
| 1 year earlier | $43.00M Ended 2018-12-31 | $5.82M Ended 2023-12-31 | $7.5K Ended 2024-12-31 | $894.0K Ended 2024-12-31 |
| 2 years earlier | $48.59M Ended 2017-12-31 | $5.99M Ended 2022-12-31 | $686.0K Ended 2023-12-31 | n/a |
| 3 years earlier | $36.15M Ended 2016-12-31 | $7.81M Ended 2021-12-31 | $284.0K Ended 2022-12-31 | n/a |
| 4 years earlier | $20.26M Ended 2015-12-31 | $9.56M Ended 2020-12-31 | n/a | n/a |